Smart-Money SignalNeutral · 45/100— Insiders are net sellers over 90 days (-$4.4M, 1 sale vs 7 buys)
Price Performance
Historical data including institutional events
Company Profile
J
Jan Mikkelsen
CEO & Executive Director
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
The company was incorporated in 2006 and is based in Hellerup, Denmark.